Literature DB >> 3480804

Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment.

P Jungers1, D Ganeval, T Hannedouche, B Prieur, G Montay.   

Abstract

Twenty patients (aged 26-70 years) with severely impaired renal function received pefloxacin twice daily for 5 days as 12 mg.kg-1 administered as a 1 h i.v. infusion, or 800 mg administered as tablets. On Day 5 the minimal and maximal plasma concentrations were 5.9 and 11.5 mg.l-1 respectively, after oral administration. The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route). The minimal concentration of unchanged drug was related to the age of the patients (infusion), but the N-oxide concentration was influenced by the degree of renal impairment (both routes). The pefloxacin levels were similar to those achieved in healthy subjects, but reduced renal function leads accumulation of its biotransformation products, especially of the N-oxide metabolite which lacks antibacterial activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3480804     DOI: 10.1007/BF00544236

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue.

Authors:  G Montay; J P Tassel
Journal:  J Chromatogr       Date:  1985-04-12

2.  Pharmacokinetics of norfloxacin in chronic renal failure.

Authors:  G Arrigo; G Cavaliere; G D'Amico; E Passarella; G Broccali
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-09

3.  Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Authors:  J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

4.  Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; H F Chambers; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

5.  Pefloxacin kinetics in cirrhosis.

Authors:  G Danan; G Montay; R Cunci; S Erlinger
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  [Treatment of septicemia and endocarditis with pefloxacine. 15 cases].

Authors:  M Wolff; B Pangon; B Regnier; E Rouveix; J Bauchet; F Vachon
Journal:  Presse Med       Date:  1986-03-08       Impact factor: 1.228

7.  Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.

Authors:  A M Frydman; Y Le Roux; M A Lefebvre; F Djebbar; J B Fourtillan; J Gaillot
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

8.  Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis.

Authors:  E Dournon; P Rajagopalan; J L Vilde; J J Pocidalo
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

9.  Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units.

Authors:  S Lauwers; W Vincken; A Naessens; D Pierard
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

10.  The efficacy of pefloxacin in comparison to gentamicin in the treatment of experimentally induced peritonitis in rats.

Authors:  C E Nord; C Edlund; G Lahnborg
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  6 in total

1.  Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.

Authors:  J L Schmit; L Hary; P Bou; H Renaud; P F Westeel; M Andrejak; A Fournier
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  Effect of renal impairment on the pharmacokinetics of grepafloxacin.

Authors:  C Efthymiopoulos; S L Bramer; A Maroli; J G Gambertoglio
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 4.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Authors:  R Bruno; M C Iliadis; B Lacarelle; V Cosson; J W Mandema; Y Le Roux; G Montay; A Durand; M Ballereau; M Alasia
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

Review 6.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.